Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

Abstract

The programmed cell death 1 (PD-1) receptor inhibitors nivolumab and pembrolizumab have demonstrated superior efficacy compared with chemotherapy or the cytotoxic T-lymphocyte–associated antigen 4 inhibitor ipilimumab in advanced melanoma, with a lower incidence of treatment-related grade 3/4 adverse events (AEs).^1-6 In phase 2 and phase 3 trials, the combination of nivolumab and ipilimumab has demonstrated significantly longer progression-free survival and a higher objective response rate compared with ipilimumab alone.^1,7-9